Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Core Insights - Jyong Biotech Ltd. has been awarded the Innovation Gold Award for its oral plant-derived investigational new drug BOTRESO® at the 2025 Taipei Biotech Awards, highlighting its commitment to innovation in the biotechnology sector [1][3][4] Company Overview - Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][5] - The company has established integrated capabilities across all key drug development functions, including drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization since its inception in 2002 [5][6] Product Development - BOTRESO® is recognized as the first Taiwan-developed oral botanical new drug to receive U.S. FDA Investigational New Drug (IND) approval and has completed four Phase III clinical trials [2][3] - The product holds multiple invention patents for its pharmaceutical composition globally and has a New Drug Application (NDA) submitted to the U.S. FDA [2][3] Recognition and Future Plans - The award received by the company underscores its leadership in plant-derived drug innovation and its ongoing commitment to delivering effective therapies to patients worldwide [4] - The company aims to expand its global presence and continue developing first-class botanical new drugs to address critical healthcare needs [4]